Study Overview: This study is testing two drugs, lovastatin and pembrolizumab, for people with head and neck cancer that has come back or spread to other body parts. Lovastatin, often used to lower cholesterol, might help kill cancer cells and make them more sensitive to pembrolizumab, a medicine that helps the immune system attack cancer cells.
Treatment Plan: Participants take lovastatin by mouth daily and receive pembrolizumab through an IV every 21 days, continuing for up to 12 months. The study includes regular scans and blood tests to check progress, and participants will be followed up for two years after treatment.
- Study Duration: Up to 12 months on treatment, plus 2 years follow-up.
- Eligibility: Adults aged 18+ with specific types of head and neck cancer.
- Requirements: Participants must not use certain other drugs and must agree to use birth control.
Important Considerations: Make sure you are not currently taking statins, have not had recent chemotherapy or radiation, and can swallow pills. Discuss any allergies or medications with your doctor to ensure this study is a good fit for you.